Keros Therapeutics, Inc. (NASDAQ:KROS) is Parkman Healthcare Partners LLC's 5th Largest Position

Parkman Healthcare Partners LLC grew its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 112.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 421,782 shares of the company's stock after buying an additional 223,155 shares during the period. Keros Therapeutics accounts for approximately 3.1% of Parkman Healthcare Partners LLC's holdings, making the stock its 5th biggest holding. Parkman Healthcare Partners LLC owned approximately 1.04% of Keros Therapeutics worth $24,493,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in KROS. KBC Group NV lifted its holdings in Keros Therapeutics by 52.0% in the 3rd quarter. KBC Group NV now owns 1,263 shares of the company's stock worth $73,000 after buying an additional 432 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in Keros Therapeutics by 26.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company's stock worth $77,000 after acquiring an additional 280 shares during the period. Values First Advisors Inc. acquired a new stake in Keros Therapeutics during the third quarter worth about $89,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Keros Therapeutics during the second quarter worth about $128,000. Finally, LMR Partners LLP acquired a new stake in Keros Therapeutics during the third quarter worth about $213,000. 71.56% of the stock is owned by hedge funds and other institutional investors.

Keros Therapeutics Stock Performance

Shares of NASDAQ:KROS traded up $5.51 during mid-day trading on Wednesday, hitting $67.79. The stock had a trading volume of 527,594 shares, compared to its average volume of 375,449. The company has a market cap of $2.75 billion, a PE ratio of -13.01 and a beta of 1.20. Keros Therapeutics, Inc. has a 12-month low of $27.31 and a 12-month high of $73.00. The company's 50 day moving average is $59.67 and its 200-day moving average is $52.37.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($1.28) by ($0.13). The firm had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The business's quarterly revenue was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.33) EPS. On average, equities research analysts predict that Keros Therapeutics, Inc. will post -5.28 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Guggenheim reiterated a "buy" rating on shares of Keros Therapeutics in a research note on Wednesday. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Thursday, November 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. Wedbush restated an "outperform" rating and issued a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Finally, Scotiabank initiated coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a "sector outperform" rating and a $77.00 target price for the company. Twelve analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average price target of $88.89.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.